www.fastcompany.com
6 months agoHealth
This $2 billion unicorn startup is corporate America's secret weapon against Ozempic
As more people seek coverage for GLP-1 medications, employers are halting coverage due to rising costs.
Virta offers a cheaper alternative to GLP-1s through its virtual platform and nutritional therapy to reverse type 2 diabetes and obesity. [ more ]